Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy

Izumi, Kiyotaka; Li, Yang; Zheng, Yian; Gordetsky, Jennifer B.; Yao, Jorge L.; Miyamoto, Hiroshi

doi:10.1016/j.humpath.2012.02.008

Cited by 23 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Appropriate approval from the institutional review board was obtained before construction and use of the TMA. Prostate TMAs, consisting of representative lesions of non‐neoplastic prostate, high‐grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma, were constructed, as described previously . None of the patients had received therapy with hormonal reagents, radiation, or other anti‐cancer drugs pre‐ or post‐operatively before clinical or biochemical recurrence.…”

Section: Methodsmentioning

confidence: 99%

Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Appropriate approval from the institutional review board was obtained before construction and use of the TMA. Prostate TMAs, consisting of representative lesions of benign, high‐grade prostatic intraepithelial neoplasia (HGPIN), and prostatic adenocarcinoma, were constructed, as described previously . None of the patients had received therapy with hormonal reagents, radiation, or other anti‐cancer drugs pre‐ or post‐operatively before clinical or biochemical recurrence.…”

Section: Methodsmentioning

confidence: 99%

The role of NFATc1 in prostate cancer progression: Cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion

et al. 2015

Self Cite

View full text Add to dashboard Cite

show abstract

“…A tissue microarray (TMA), consisting of representative lesions (three cores each) of benign appearing prostate and prostatic carcinoma from the tissue specimens obtained by radical prostatectomy, was constructed, as described previously [20] . Appropriate approval from the Institutional Review Board was obtained before construction and use of the TMA.…”

Section: Methodsmentioning

confidence: 99%

The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status

Lin¹,

Lin²,

Yang³

et al. 2015

Neoplasia

Self Cite

View full text Add to dashboard Cite

The insulin sensitizers, thiazolidinediones (TZDs), have been used as anti-diabetic drugs since the discovery of their ability to alter insulin resistance through transactivation of peroxisome proliferator-activated receptors (PPARs). However, their side effects in hepatitis, cardiovascular diseases, and bladder cancer resulted in some selling restrictions in the USA and Europe. Here, we found that the potential impact of TZDs on the prostate cancer (PCa) progression might be linked to the TR4 nuclear receptor expression. Clinical surveys found that 9% of PCa patients had one allele TR4 deletion in their tumors. TZD increased cell growth and invasion in PCa cells when TR4 was knocked down. In contrast, TZD decreased PCa progression in PCa cells with wild type TR4. Mechanism dissection found that the Harvey Rat Sarcoma (HRAS) oncogene increased on TZD treatment of the TR4 knocked-down CWR22Rv1 and C4-2 cells, and interruption with HRAS inhibitor resulted in reversal of TZD-induced PCa progression. Together, these results suggest that TZD treatment may promote PCa progression depending on the TR4 expression status that may be clinically relevant since extra caution may be needed for those diabetic PCa patients receiving TZD treatment who have one allele TR4 deletion.

show abstract

Seminal plasma proteins in prostatic carcinoma: increased nuclear semenogelin I expression is a predictor of biochemical recurrence after radical prostatectomy

Cited by 23 publications

References 14 publications

Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine

Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine

The role of NFATc1 in prostate cancer progression: Cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion

The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status

Contact Info

Product

Resources

About